Novartis is “actively” managing its existing relationships with Chinese service providers to mitigate risks if the Biosecure Act passes.
Par Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Par's Generic Topiramate Receives Receives Approval in the U.S.
Par's Generic Bismuth Subcitrate Potassium, Tetracycline Hydrochloride &Metronidazole Receives Approval in the U.S.
Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements.
Two more pharmaceutical companies are having difficulty supplying Adderall to US patients with attention-deficit/hyperactivity disorder as shortages plague the market.
(Reuters) - Endo International's Par Pharmaceutical Inc on Wednesday failed to persuade a U.S. appeals court to revive its lawsuit seeking to block Eagle Pharmaceuticals Inc from selling a generic version of Par's best-selling blood-pressure drug Vasostrict.
Par Pharmaceutical`s Generic Adapalene|Benzoyl Peroxide Receives Approval in the U.S.